Navigation Links
Cancer detection from an implantable, flexible LED
Date:9/19/2011

Daejeon, the Republic of Korea, August 8, 2011Can a flexible LED conformably placed on the human heart, situated on the corrugated surface of the human brain, or rolled upon the blood vessels, diagnose or even treat various diseases? These things might be a reality in the near future.

The team of Professor Keon Jae Lee (Department of Materials Science and Engineering, KAIST) has developed a new concept: a biocompatible, flexible Gallium Nitride (GaN) LED that can detect prostate cancer.

GaN LED, a highly efficient light emitting device, has been commercialized in LED TVs and in the lighting industry. Until now, it has been difficult to use this semiconductor material to fabricate flexible electronic systems due to its brittleness. The research team, however, has succeeded in developing a highly efficient, flexible GaN LED and in detecting cancer using a flexible LED biosensor.

Prof. Lee was involved in the first co-invention of "High Performance Flexible Single Crystal GaN" during his PhD course at the University of Illinois at Urbana-Champaign (UIUC). This flexible GaN LED biosensor utilized a similar protocol to transfer thin GaN LED films onto flexible substrates, followed by a biocompatible packaging process; the system's overall potential for use in implantable biomedical applications was demonstrated.

Professor John Roger (Department of Materials Science and Engineering, UIUC) said,

"Bio-integrated LEDs represent an exciting, new technology with strong potential to address important challenges in human health. This present work represents a very nice contribution to this emerging field."


'/>"/>

Contact: Lan Yoon
hlyoon@kaist.ac.kr
82-423-502-295
The Korea Advanced Institute of Science and Technology (KAIST)
Source:Eurekalert  

Page: 1

Related biology technology :

1. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
2. Some Patients Paying for Their Prostate Cancer Surgery for the Rest of Their Lives
3. OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
4. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
5. More Precise Prostate Cancer Screening on Horizon
6. New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology
7. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
8. Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
9. Novel Flavonoid Compounds That Significantly Reduce Cancer Cell Growth Are Available For Further Research and Development as Anti-Cancer Therapeutics
10. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
11. Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine -- Treatments Not Yet Offered in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer detection from an implantable, flexible LED
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... June 22, 2016  Mesa Biotech Inc., a ... testing platform designed specifically for point-of-care (POC) infectious ... scientific advisory board (SAB). Approved by the executive ... is chartered to advise on the development and ... Led by Dr. Steve Young , this ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):